SERIES B FUNDING MEANING DRIVER
SERIES B FUNDING MEANING FULL
SERIES B FUNDING MEANING PROFESSIONAL

You want a management team and investor syndicate that is willing to kill programs as early as possible if they don’t work.

Have an intellectually honest “truth seeking” culture.

SERIES B FUNDING MEANING PROFESSIONAL

While you want diversity on your management team, you need people with technical and professional experience in the various aspects of drug development. Have some experience on the management team.

Take advantage of expedited FDA pathways like accelerated approval, breakthrough designation, fast track, etc.

Homogenous, well-defined, ideally genetically defined patient populations.

Phase 1 or 2 study with biomarker endpoints that are predictive of clinical outcomes endpoints.

Reducing the cost and risk of your clinical program is important

SERIES B FUNDING MEANING DRIVER

Phase 2 / 3 failure is the biggest driver of the cost of drug development.

Have a tractable clinical development plan: can get initial data on whether the drug is effective in humans quickly / cheaply.

Have robust data to show the target is valid, the molecule hits the target enough / the right way / without too much non-specific activity, the molecule has drug-like qualities, is safe, etc.

Have good disease models that correlate with human clinical outcomes.

If you are developing some chemical / biologic that can drug a pathway or target that is known to be a big driver of disease but hasn’t previously been druggable, you can get a sense for whether it’s working a bit earlier / for less money.

That takes a long time and a lot of money, and the risk that it works in animals / in vitro but fails in people is high

If you are drugging a novel target, you really won’t know if it “works” until you test it in people.

Have some novel biological / biochemical insight that gives them a better understanding of disease biology or a better way to hit a well-understood target.

Develop drugs for severe unmet medical needs (ie cancer, or severe / neglected rare diseases).

More qualitatively, successful biotech startups: This data comes from our startup database and analysis of IPO prospectuses. If we define “top biotech startups” as “biotech startups that went public from 2018-Q1 2019” (here I’m just focused on therapeutics companies, not device, diagnostic, agtech, etc): It’s hard to find comprehensive data on CEO age and biotech startup performance, but I did a writeup of this topic here. If we define “top biotech startups” as “innovative biotherapeutics companies started in the last 50 years that were acquired for or currently trade at $10B+”, the most surprising characteristic is that most of these companies have relatively inexperienced CEOs (CEOs under the age of 40). What are the characteristics of the top biotech startups? If you're searching for companies that don't meet any of those criteria, you'll get more search results if you leave at least one search field blank. Most VC-backed startups these days are oncology or rare disease companies at preclinical stage or earlier, and most are located in the San Francisco Bay Area or Boston. Search for biotech startups and investors that have raised money or made investments since January 2018. I use 'biotech' and 'biopharma' interchangeably. So no diagnostics, tools, devices or service companies.

SERIES B FUNDING MEANING FULL

You can check out our full database of biotech startups that have raised over $47B since 2018 here.Ī quick note on terminology: in this post (as in all my other posts), I define 'biotech' as companies developing FDA-regulated prescription medicines. A qualitative and quantitative description of the characteristics of companies that receive venture funding.A list of biopharma startups that raised venture capital in the last 30 days.A tool for searching for biotech startups and investors by disease area, development stage and location.Where is this money going? This post will examine the kinds of biotech startups that venture capitalists are investing in. 2020 is shaping up to be the biggest year for biotech venture funding on record, with almost $17B invested in biopharma startups through Q3 2020.

Series b funding meaning